These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 24664619)

  • 21. Clinical Review: Safety and Efficacy Comparison between Sulfonylureas and Dipeptidyl Peptidase-4 Inhibitors as Second-Line Therapies in Type 2 Diabetes Mellitus.
    Gillani SW; Moosvi AF
    Curr Pharm Des; 2020; 26(34):4315-4322. PubMed ID: 32268860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testing the therapeutic equivalence of alogliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin as monotherapy or in combination with metformin in patients with type 2 diabetes.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Diabetes Ther; 2014 Jun; 5(1):341-4. PubMed ID: 24793219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis.
    McIntosh B; Cameron C; Singh SR; Yu C; Dolovich L; Houlden R
    Open Med; 2012; 6(2):e62-74. PubMed ID: 23696771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Behavioural interventions for type 2 diabetes: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(21):1-45. PubMed ID: 23074526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.
    Thomas MC; Paldánius PM; Ayyagari R; Ong SH; Groop PH
    Diabetes Ther; 2016 Sep; 7(3):439-54. PubMed ID: 27502495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.
    Li CJ; Liu XJ; Bai L; Yu Q; Zhang QM; Yu P; Yu DM
    Diabetol Metab Syndr; 2014; 6():69. PubMed ID: 24917890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
    Geng J; Yu H; Mao Y; Zhang P; Chen Y
    Pharmacoeconomics; 2015 Jun; 33(6):581-97. PubMed ID: 25736235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
    McIntosh B; Cameron C; Singh SR; Yu C; Ahuja T; Welton NJ; Dahl M
    Open Med; 2011; 5(1):e35-48. PubMed ID: 22046219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials.
    Esposito K; Chiodini P; Maiorino MI; Bellastella G; Capuano A; Giugliano D
    BMJ Open; 2014 Jun; 4(6):e005442. PubMed ID: 24916090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.
    Schwartz SL
    Am J Geriatr Pharmacother; 2010 Oct; 8(5):405-18. PubMed ID: 21335294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
    Goring S; Hawkins N; Wygant G; Roudaut M; Townsend R; Wood I; Barnett AH
    Diabetes Obes Metab; 2014 May; 16(5):433-42. PubMed ID: 24237939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis.
    Hou L; Zhao T; Liu Y; Zhang Y
    Exp Ther Med; 2015 Apr; 9(4):1528-1536. PubMed ID: 25780464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.
    Wu S; He Y; Wu Y; Ji Y; Hou L; Liu X; Ge Y; Yu Y; Yu Y; Wei Y; Qian F; Luo Q; Feng Y; Feng Y; Wang J; Huo M; Li H; Xue F; Liu Y
    Front Endocrinol (Lausanne); 2022; 13():897776. PubMed ID: 36034458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
    Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
    PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis.
    Cai X; Gao X; Yang W; Han X; Ji L
    Diabetes Ther; 2018 Oct; 9(5):1995-2014. PubMed ID: 30155646
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.